The combination of urinary follistatin with standard clinical parameters and/or established AKI biomarkers will be advantageous for monitoring of the stage of tubular recovery and assessment of the appropriate timing of intervention for patients with AKI. The gene discussed is FST; the disease is acute kidney injury.